Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Cook, G orcid.org/0000-0003-0223-3652, Parrish, C, Yong, K et al. (12 more authors) (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Metadata

Authors/Creators:

Cook, G https://orcid.org/0000-0003-0223-3652
Parrish, C
Yong, K
Cavenagh, J
Snowden, JA
Drayson, MT
Garg, M
Cairns, D https://orcid.org/0000-0002-2338-0179
Ashcroft, J
Striha, A https://orcid.org/0000-0003-3363-8417
Hockaday, A
de Tute, RM
Owen, RG
Williams, C
Cook, M

Dates:

Published: 29 November 2018

Institution:

The University of Leeds

Academic Units:

The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)

Funding Information:

Funder	Grant number
Cancer Research UK	A19272

Depositing User:

Symplectic Publications

Date Deposited:

17 Feb 2020 11:18

Last Modified:

29 Jun 2020 13:36

Status:

Published

Publisher:

American Society of Hematology

Identification Number:

https://doi.org/10.1182/blood-2018-99-112116

Related URLs:

Author

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)